Clinical Trials Logo

BRAF V600 Mutation clinical trials

View clinical trials related to BRAF V600 Mutation.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06054191 Not yet recruiting - NSCLC Clinical Trials

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase II, two parallel group study assessing the efficacy and safety of neoadjuvant and adjuvant targeted therapy in patients with stage IB-IIIA NSCLC harboring BRAF V600 or MET exon14 mutations.

NCT ID: NCT05275374 Not yet recruiting - Cancer Clinical Trials

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

ENHANCE
Start date: December 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF V600 mutation. This study is divided into three stages: Phase Ia: a dose-escalation phase of XP-102; Phase Ib: a dose-escalation and sample size expansion phase of XP-102 plus trametinib; Phase IIa: an expansion phase of XP-102 plus trametinib.